Key Insights Cellectis' Annual General Meeting to take place on 26th of June Total pay for CEO Andre Choulika includes...
3 days ago

As of December 31, 2024, Cellectis had $264 million in consolidated cash, cash equivalents, restricted cash and fixed-term deposits classified as current-...
3 months ago

Despite these insights, Cellectis said UCART123 is being deprioritized so the company's resources can be focused on its two other CAR-Ts. These...
7 months ago

AstraZeneca has invested $140 million in Cellectis, acquiring new preferred shares at $5.00 each. This substantial capital infusion from a...
2 months ago

Cellectis' Annual Shareholders General Meeting to be Held on June 26, 2025 ... Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company...
1 month ago

Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025Eti-cel (UCART20x22) Phase 1...
1 month ago

Summary · Cellectis SA's pipeline consists of allogeneic CAR T-cell therapies that have the potential to make meaningful dents in heme...
1 month ago

Cellectis has also strengthened its collaboration with AstraZeneca, which includes an additional equity investment of $140 million, ensuring...
3 months ago

Cellectis operates in the highly competitive CAR T therapy space, where several large pharmaceutical companies and biotechnology firms are vying...
1 month ago

In this work, Cellectis combines TALEN®-mediated gene editing with non-viral delivery of transgene for advancing cellular and gene therapies,...
1 month ago